Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®

Laurent Magnenat; A. Palmese; C. Frémaux; F. D'Amici; Mariagrazia Terlizzese; M. Rossi; Laurent Chevalet

DOI:10.1080/19420862.2016.1259046

Corpus ID: 3693807

Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®

@article{Magnenat2017DemonstrationOP,
  title={Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®},
  author={Laurent Magnenat and A. Palmese and C. Fr{\'e}maux and F. D'Amici and Mariagrazia Terlizzese and M. Rossi and Laurent Chevalet},
  journal={mAbs},
  year={2017},
  volume={9},
  pages={127 - 139}
}

Laurent Magnenat, A. Palmese, +4 authors Laurent Chevalet

Published 2017

Chemistry, Medicine

mAbs

ABSTRACT Biosimilars are biological products that are highly similar to existing products approved by health authorities. Demonstration of similarity starts with the comprehensive analysis of the reference product and its proposed biosimilar at the physicochemical and functional levels. Here, we report the results of a comparative analysis of a proposed biosimilar adalimumab MSB11022 and its reference product, Humira®. Three batches of MSB11022 and up to 23 batches of Humira® were analyzed by a… CONTINUE READING

View on Taylor & Francis

Share This Paper

26 Citations

Highly Influencial Citations

Background Citations

Methods Citations

Topics from this paper

Explore Further: Topics Discussed in This Paper

Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab

N. Lee, J. J. Lee, +6 authors Gwangmin Park
Mathematics, Medicine
mAbs
2019

Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira® in healthy subjects

Elizabeth Hyland, T. Mant, +4 authors Volker Wagner
Medicine
British journal of clinical pharmacology
2016

Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses

Jihun Lee, H. Kang, +5 authors Shin Jae Chang
Biology, Medicine
mAbs
2018

Insight into Biosimilars: Short Description, Analytical Assessment and Market

Assessment of biosimilarity under native and heat-stressed conditions: rituximab, bevacizumab, and trastuzumab originators and biosimilars

Jukyung Kang, Troy Halseth, +5 authors Anna Schwendeman
Chemistry, Medicine
Analytical and Bioanalytical Chemistry
2019

Reporting of quality attributes in scientific publications presenting biosimilarity assessments of (intended) biosimilars: a systematic literature review.

Ali M Alsamil, Thijs J. Giezen, +4 authors H. Gardarsdottir
Medicine
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
2020

S. Gerdes, U. Mrowietz, +5 authors Marc A. Radtke
Medicine
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
2018